抗体极致战略
Search documents
优宁维:公司围绕一站式平台极致战略和抗体极致战略,致力于通过围绕抗体上下游应用领域寻找相关标的企业
Zheng Quan Ri Bao Wang· 2025-12-26 11:43
证券日报网讯12月26日,优宁维(301166)在互动平台回答投资者提问时表示,公司围绕一站式平台极 致战略和抗体极致战略,致力于通过围绕抗体上下游应用领域寻找相关标的企业,以实现与现有业务的 协同发展。公司将严格遵守信息披露相关规定,如有需要披露的实质性进展或达到披露标准的交易,将 及时发布公告。 ...
优宁维(301166) - 301166优宁维投资者关系管理信息20250429
2025-04-29 13:17
Financial Performance - In 2024, the company's operating revenue decreased by 8.82% year-on-year, while net profit attributable to shareholders dropped by 74.83%, with a non-recurring net profit of -15.11 million yuan [2] - The decline in revenue is attributed to changes in downstream market demand, intensified competition in the domestic life sciences service market, and increased operational costs due to the completion of the self-owned brand product production base project [2][3] Brand Performance - Revenue from self-owned brands (Absin, LabEx, etc.) grew by nearly 30% year-on-year, while revenue from third-party brands declined significantly due to market competition [3][6] - The self-owned brand business, which accounts for over 90% of total revenue, faced substantial impacts from the downturn in third-party brand sales [3] Strategic Initiatives - The company aims to enhance its core competitiveness through a dual strategy of internal growth and external expansion, focusing on product pipeline enhancement, supply chain investment, and information technology [4] - Plans to accelerate the overseas expansion of self-owned brands, including the establishment of a subsidiary in Singapore and participation in online and offline promotional activities [4][5] Cost Management - The company continues to invest in marketing, product expansion, supply chain, and R&D to maintain service capabilities and improve the revenue share of self-owned products [2][4] - Direct sales decreased by 12.74%, prompting a shift towards distribution channels to reach price-sensitive customers [4] R&D and Innovation - As of the end of 2024, the company’s antibody R&D center in Hangzhou has developed over 2,900 products, while the protein R&D center in Nanjing has developed over 1,700 products [5] - The company is committed to leveraging information technology to enhance operational efficiency and customer service [7] Compliance and Safety - The company has established safety management systems and protocols to ensure compliance and safety in hazardous waste management [7]